Table 5.
Summary of subjects with an overall response of stable disease or better
| Subject (Age/Sex) and Cohort (Dose) | Tumor type | Best response (Tumor response) | Weeks on treatment (Main phase/Extension phase) | VEGF-A Baseline (pg/mL) | Largest VEGF-A Decrease (% Change from baseline) |
|---|---|---|---|---|---|
| 55 / Female | Ovarian | SD (3.5%) | 16.4 / No | 300 | −13.0% |
| Part 1, Cohort 2 (8 mg/kg biw) 59 / Male | Colorectal | SD (−3.1%) | 15.1 / No | 753 | −22.4% |
| Part 1, Cohort 2 (8 mg/kg biw) 77 / Female# | Non-small cell lung | SD (−3.4%) | 24.0 / Yes | 2150 (High) | −75.9% |
| Part 1, Cohort 4 (24 mg/kg biw) 76 / Female# | Colorectal | PR (−37.5%) | 25.0/Yes | 3620 (High) | −96.9% |
| Part 1, Cohort 5 (24 mg/kg qw) 52 / Female | Ovarian | SD (2.6) | 22.0 / No | 982 | −3.9% |
| Part 2 (24 mg/kg qw) 76 / Female# | Ovarian | SD * | 23.9/Yes | 18,600 (High) | −45.0% |
| Part 2 (24 mg/kg qw) 29 / Female | Ovarian | SD (2.9) | 24.0 / Yes | 171 | 5.2% |
| Part 2 (24 mg/kg qw) |
Tumor response was determined by percent change from baseline in the sum of longest diameters of the target lesions. High baseline VEGF-A levels were defined as >1500 pg/mL.
#
Indicates the three notable subjects of interest (Subjects 1, 2, and 3) with high baseline VEGF-A and clinical benefit discussed further in the text.
*
Tumor size was not assessable by RECIST for this subject. Biw = every two weeks; qw = every week